We know development. Here is what our scientists think about it.
Decisions across a drug program, from selecting a lead candidate to setting a clinical dose, rely on measuring the drug and its effects in biological samples. As a molecule moves through development, the method behind those measurements has to change with it. A research method that supports lead optimization is not the fully developed method […]
Delivery technology no longer just supports new therapies; it is one of the main things that make them possible. That was the shared conclusion of the final panel at Ardena’s Nanomedicine and Bioconjugation Symposium, held on September 15 and 16, 2026, in Oss, the Netherlands. Over two days, clinical researchers, academics, bioprocess engineers and bioanalytical […]
Nanomedicine has progressed far beyond its early role as an experimental drug-carrier toolbox. That is the premise of “Nanomedicine beyond carriers: devices, cells & living therapeutics”, a collaborative review published in Biomedical Microdevices on 8 September 2026, in the Special Issue dedicated to the NanoDDS 2025 conference. Silvie Meeuwissen, Director Process R&D and Manufacturing, Nanomedicines […]
Biomarkers create the biological context for your study, turning a clinical question into a measurable answer. This article outlines how to use Ardena’s new Biomarker Catalogue to streamline the path from marker selection to quotation. Few decisions in a development programme carry as much weight per sample as the choice of biomarkers. The right combination […]
Tablets remain the way most of the world takes its medicine – yet developing a robust one is still surprisingly empirical. With the new STYL’ONE Evo Compaction Simulator at our Ghent site, we can now predict how a formulation will behave on a production tablet press or roller compactor from the very first development batch, […]
For most of the last decade, protein quantification in biological matrices has been the territory of the ligand binding assay. That has not changed, but the boundaries have. A new perspective from the European Bioanalysis Forum (EBF) Hybrid MS team, published in Bioanalysis, gathers seven case studies from pharmaceutical companies and CROs showing where liquid […]
Multiple possibilities, one decision Pediatric formulation development usually starts with understanding the exact drug product (DP) requirements followed by subsequent benchmarking against the available formulation options as there is no such thing as one technology fits all. Before starting, the above evaluation sets the taste masking, the stability profile, the final presentation, and the age […]
LNP manufacturing has become one of the fastest-growing areas in modern pharmaceutical development. Lipid nanoparticles (LNPs) have moved from a niche formulation approach to one of the most validated platforms for delivering complex therapeutic payloads, and demand for specialized development and manufacturing partners has grown alongside them. According to market research firm InsightAce Analytic, the […]
HPAPI contract manufacturing companies are not interchangeable, and choosing the right one is among the highest-stakes decisions in a potent-compound program. Pick the wrong partner and it surfaces later: as a containment finding, a failed cleaning validation, or a technology transfer that stalls before your first batch. This guide is about how to make that […]
In the fast-paced world of early-phase drug development, successful formulation development is often the bridge between a promising molecule and a viable clinical candidate. During BIO 2026 in San Diego, Henny Zijlstra, Chief Commercial Officer at Ardena, sat down with BioPharma Boardroom to discuss how integrated CDMO strategies are shaping the future of early-phase pipelines. […]
Measuring the size of nanomaterials is a critical step in developing safe and effective drug products in modern nanomedicine. Dynamic light scattering (DLS) is the most commonly used technique for this purpose in pharmaceutical industry due to its simplicity. It has, however, low resolution (if the product contains two size populations, such as 50 and […]
The modern pharmaceutical pipeline is rich in highly potent, highly specific New Chemical Entities (NCEs). Yet, approximately 70% to 90% of new chemical entities and up to 40% of marketed drugs fall within BCS Class II or IV, reflecting the widespread challenge of poor aqueous solubility. When a molecule crosses your desk as a “brick […]
